Before he won a Fields Medal for his pioneering work balancing randomness and order, Yu Deng first had to achieve equilibrium ...
Clinical Trials Arena on MSN
Another win for Lilly’s triple-g agonist in two more Phase III trials
If approved, Lilly’s triple-g agonist would become the company’s fifth glucagon-based drug to be marketed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results